Society
NAFDAC breaks silence on viral claim about ban of popular malaria drug
By Kazeem Ugbodaga
The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed claims circulating on social media that Camosunate, an antimalarial medicine containing artesunate and amodiaquine, has been banned in Nigeria.
The agency clarified that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination, describing the viral claim as false.
In a press release dated November 21, 2026, NAFDAC said some of the symptoms mentioned in the circulating report could be associated with known side effects of the medicine.
These include nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite.
However, the agency urged anyone who suspects an adverse reaction to the medicine to report it to NAFDAC for proper assessment.
It encouraged members of the public and healthcare professionals to report suspected adverse drug reactions through the NAFDAC Med Safety App, which is available for download on Android and iOS devices, or at the nearest NAFDAC office.
NAFDAC also appealed to Nigerians to stop sharing the false information, warning that the circulation of unverified claims could generate unnecessary public concern.
The agency further urged those who had already shared the claim to circulate its clarification through the same channels to help counter misinformation.
The statement was signed by NAFDAC Director-General and Chief Executive Officer, Prof. Mojisola Adeyeye.















